Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study

Mariane de Montalembert, Ersi Voskaridou, Lena Oevermann, Giovanna Cannas, Anoosha Habibi, Gylna Loko, Laure Joseph, Raffaella Colombatti, Pablo Bartolucci, Valentine Brousse, Frédéric Galactéros, All ESCORT HU Investigators, Mariane de Montalembert, Ersi Voskaridou, Lena Oevermann, Giovanna Cannas, Anoosha Habibi, Gylna Loko, Laure Joseph, Raffaella Colombatti, Pablo Bartolucci, Valentine Brousse, Frédéric Galactéros, All ESCORT HU Investigators

Abstract

Several controlled studies have evidenced good efficacy and short-term and mid-term safety profiles for hydroxyurea (HU), which has become the cornerstone for prevention of sickle-cell disease (SCD)-related vaso-occlusive crises. However, there are few large-scale reports on its long-term use and certain caregivers and patients have concerns about its safety. Following the licensing of HU in Europe for children and adults with severe forms of SCD, ESCORT-HU was designed as a Phase IV observational cohort study. It included 1906 participants, of whom 55% were adults. The most common hemoglobin (Hb) genotypes were HbSS (84.7%) and HbSβ+ (7.0%). The median duration of follow-up was 45 months, for a total of 7309 patient-years of observation. The dose of HU after 1 year was 20.6 mg/kg/d for children and 16.3 mg/kg/d for adults. There was a statistically significant decrease in the number of vaso-occlusive episodes lasting >48 h, acute chest syndrome episodes, hospitalizations, and the percentage of patients requiring blood transfusions within the first 12 months relative to the year before enrolment. Neutropenia and thrombocytopenia were the most commonly reported adverse effects. No new HU toxicity was identified. Overall, 125 pregnancies were reported in 101 women and no malformations were observed in the neonates. There were 12 pregnancies for partners of male patients treated with HU. One case of fatal myelodysplastic syndrome was reported, for which a causal association with HU could not be excluded. This cohort study of patients with SCD highlights the positive benefit-to-risk ratio of HU in children and adults.

Trial registration: ClinicalTrials.gov NCT02516579.

© 2021 Wiley Periodicals LLC.

References

REFERENCES

    1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390:311-323.
    1. Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a pan-European consensus conference. Br J Haematol. 2018;183:648-660.
    1. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol. 2003;120:177-186. Erratum in: Br J Haematol. 2003; 121:200.
    1. Athanassiou G, Moutzouri A, Kourakli A, Zoumbos N. Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia. Clin Hemorheol Microcirc. 2006;35:291-295.
    1. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol. 1989;32:104-111.
    1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of Hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
    1. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88:1960-1964.
    1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
    1. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354-2263.
    1. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
    1. Shih S, Cohen LL. A systematic review of medication adherence interventions in pediatric sickle cell disease. J Pediatr Psychol. 2020;45:593-606.
    1. Pecker LH, Kappa S, Greenfest A, Darbari DS, Nickel RS. Targeted Hydroxyurea education after an emergency department visit increases Hydroxyurea use in children with sickle cell anemia. J Pediatr. 2018;201:221-228.
    1. Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018;35:297-308.
    1. Fisak B, Belkin MH, von Lehe AC, Bansal MM. The relation between health-related quality of life, treatment adherence and disease severity in a paediatric sickle cell disease sample. Child Care Health Dev. 2012;38:204-210.
    1. Smaldone A, Manwani D, Aygun B, et al. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. BMC Pediatr. 2019;19:354.
    1. Cervi A, Diamantouros A, Azzam M, Lane SJ, Sapru H, Verhovsek M. Pharmacy hydroxyurea education materials for patients with sickle cell disease: an environmental scan and assessment of accuracy. Pediatr Blood Cancer. 2020;67:e28179.
    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
    1. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusion changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase, non-inferiority trial. Lancet. 2016;387(10019):661-670.
    1. Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of Hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130:2585-2593.
    1. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105:2685-2690.
    1. De Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91:125-128.
    1. Quarmyne MO, Dong W, Theodore R, et al. Hydroxyurea effectiveness in children with sickle cell anemia: a large retrospective, population bases cohort. Am J Hematol. 2017;92:77-81.
    1. Rigano P, De Franceschi L, Sainati L, et al. Real-life experience with hydroxyurea in sickle cell disease: a multicenter study in a cohort of patients with heterogeneous descent. Blood Cells Mol Dis. 2018;69:82-89.
    1. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122:1332-1342.
    1. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939-955.
    1. Aumont G, Driss F, Lazure T, et al. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol. 2015;90:131-132.
    1. Ware RE, Dertinger SD. Absence of hydroxyurea-induced mutational effects supportshigher utilisation for the treatment of sickle cell anaemia. Br J Haematol. 2021;194(2):252-266. .
    1. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among patients with sickle cell disease in California. Blood. 2017;130:1597-1599.
    1. Ballas SK, McCarthy WF, Nan Guo BS, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101:1046-1051.
    1. Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15:1309-1311.
    1. Osegbe DN, Akinyanju O, Amaku EO. Fertility in males with sickle cell disease. Lancet. 1981;2:275-276.
    1. Berthaut I, Guignedoux G, Kirsh-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93:988-993.
    1. Gille AS, Pondarre C, Dalle JH, et al. Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease. Blood. 2021;137:856-859.
    1. DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. Expert Rev Hematol. 2014;7:767-773.
    1. Habibi A, Fois E, Cannas G, et al. Management of male fertility in sickle cell disease before and after hydroxycarbamide. Blood. 2017;103(Suppl. 1):2260.
    1. Joseph L, Jean C, Manceau S, et al. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease. Blood. 2021;137:826-829.
    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease. Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033-1048.
    1. Qureshhi A, Kaya B, Pancham S, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. Br J Haematol. 2018;181:460-475.
    1. John CC, Opoka RO, Latham TS, et al. Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2020;382:2524-2533.
    1. Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380:121-131.
    1. Ofakunrin AOD, Aguche S, Adekola K, et al. Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, north Central Nigeria. J Trop Pediatr. 2020;66:290-298.
    1. Galandanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial. Am J Hematol. 2020;95:E247-E250.
    1. De Montalembert M, Tshilolo L, Allali S. Sickle cell disease: a comprehensive program of care from birth. Hematology Am Soc Hematol Educ Program. 2019;2019:490-495.
    1. Ataga KI, Kutlar A, Kanter J, et al. Crizanluzimab for the prevention of pain crises inn sickle cell disease. N Engl J Med. 2017;376:429-439.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere